The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 101-59-87
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Borzilova Yu.A.

Northwest State Medical University named after I.I. Mechnikov, Ministry of Health of the Russian Federation, 41 Kirochnaya St., St. Petersburg, 191015;
Rostov State Medical University, Ministry of Health of the Russian Federation, 29 Nakhichevanskiy pereulok, Rostov-on-Don, Russian Federation, 344022

Boldyreva L.A.

Rostov State Medical University, Ministry of Health of the Russian Federation, 29 Nakhichevanskiy pereulok, Rostov-on-Don, Russian Federation, 344022

Shlyk I.V.

Pavlov First St. Petersburg State Medical University of Healthcare Ministry of the Russian Federation

Vascular endothelial growth factors (VEGF): role in pathological processes

Authors:

Borzilova Yu.A., Boldyreva L.A., Shlyk I.V.

More about the authors

Journal: Russian Annals of Ophthalmology. 2016;132(4): 98‑103

DOI: 10.17116/oftalma2016132498-103

Views: 3246

Downloaded: 183

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Borzilova YuA, Boldyreva LA, Shlyk IV. Vascular endothelial growth factors (VEGF): role in pathological processes. Russian Annals of Ophthalmology. 2016;132(4):98‑103. (In Russ.)
https://doi.org/10.17116/oftalma2016132498-103

Подписка 2025 (Russian Annals of Ophthalmology)
 
МСФ на ЯМ
Close metadata
Recommended articles:
Choroidal changes in patients with diabetes mellitus. Russian Annals of Ophthalmology. 2023;(6):158-165
Obje­ctive functional moni­toring of reti­noprotective treatment in diabetic reti­nopathy. Russian Annals of Ophthalmology. 2024;(1):45-56
Outcomes of bima­nual vitreoretinal surgery in the treatment of diabetic reti­nopathy complications. Russian Annals of Ophthalmology. 2024;(2-2):21-27
Prevention of type 1 diabetes mellitus in children and adolescents. Russian Journal of Preventive Medi­cine. 2024;(1):115-120
Bili­rubin is a promising target for meta­bolic and athe­rosclerotic cardiovascular diseases. Russian Journal of Preventive Medi­cine. 2024;(1):121-127
Rela­tionship between carbohydrate meta­bolism diso­rders and the resi­dential area infrastructure: an epidemiological study. Russian Journal of Preventive Medi­cine. 2024;(2):51-57
Endo­thelial dysfunction as a pathogenetic factor of sensorineural hearing loss. Russian Bulletin of Otorhinolaryngology. 2024;(1):21-27
Causes of hospital mortality in adults based on medi­cal certificates of death. Russian Journal of Preventive Medi­cine. 2024;(3):7-13
Opti­mizing the treatment of diabetic ketoacidosis. Russian Journal of Anesthesiology and Reanimatology. 2024;(2):67-77
Modern issues of lung tube­rculosis and diabetes mellitus on the toba­cco consumption background in the world and the Russian Fede­ration. Russian Journal of Preventive Medi­cine. 2024;(4):97-102

Russian and foreign literature sources on vascular endothelial growth factors (VEGF) from different parts of the human body, their prevalence and involvement in pathological processes were analyzed. A conclusion has been drawn that further research on different types of VEGF is needed.

Keywords:

vascular endothelial growth factors
VEGF
diabetic retinopathy
diabetes mellitus
eye

Authors:

Borzilova Yu.A.

Northwest State Medical University named after I.I. Mechnikov, Ministry of Health of the Russian Federation, 41 Kirochnaya St., St. Petersburg, 191015;
Rostov State Medical University, Ministry of Health of the Russian Federation, 29 Nakhichevanskiy pereulok, Rostov-on-Don, Russian Federation, 344022

Boldyreva L.A.

Rostov State Medical University, Ministry of Health of the Russian Federation, 29 Nakhichevanskiy pereulok, Rostov-on-Don, Russian Federation, 344022

Shlyk I.V.

Pavlov First St. Petersburg State Medical University of Healthcare Ministry of the Russian Federation

List of references:

  1. Senger DR. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219(4587):983-985.  doi:10.1126/science.6823562 
  2. Ferrara N. Vascular Endothelial Growth Factor: Basic Science and Clinical Progress. Endocrine Reviews. 2004;25(4):581-611.  doi:10.1210/er.2003-0027 
  3. Connolly DT. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest. 1989;84 (5):1470-1478. doi:10.1172/jci114322 
  4. Keck PJ. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 1989;246(4935):1309-1312. doi:10.1126/science.2479987
  5. Plouet J, Moukadiri H. Characterization of the receptor to vasculotropin on bovine adrenal cortex-derived capillary endothelial cells. J Biol Chem. 1990; 265(36):22071-22074.
  6. Shibuya M. Vascular endothelial growth factor receptor-1: a dual regulator for angiogenesis. Angiogenesis. 2006;9:225-230.  doi:10.1007/s10456-006-9055-8 
  7. Neufeld G, Cohen T, Shrada N et al. The neurophilins: multifunctional semaphoring and VEGF receptors that modulate axon guidance and angiogenesis. Trends Cardiovase Med. 2002;12:13-19.  doi:10.1016/s1050-1738(01)00140-2 
  8. Robinson CJ, Stringer SE. The splice variant of vascular endothelial growth factor (VEGF) and their reseptor. J Cell Sci. 2001;114(5):853-865.
  9. Eriksson A. Placenta Growth Factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers. Cancer Cell. 2002;1:99-108.  doi:10.1016/s1535-6108(02)00028-4
  10. Bhisitkil RB. Vascular endothelial growth factor biology:clinical implications for ocular treatment. Br J Ophthalmol. 2006;90(12):1542-1547. doi:10.1136/bjo.2006.098426 
  11. Ferrara N, Gerber HP, Le Couter J. The biology of VEGF and its reseptors. Nat Med. 2003;9(6):669-676.  doi:10.1038/nm0603-669
  12. Levy AP. Transcriptional regulation of vascular endothelial growth factor gene by Hypoxia. J Biol Chem. 1995;270(22):13333-13340. doi:10.1074/jbc.270.22.13333 
  13. Levy AP, Levy NS, Goldberg MA. Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J Biol Chem. 1996;271(5):2746-2753. doi:10.1074/jbc.271.5.2746 
  14. Levy NS. Hypoxic stabilization of vascular endothelial growth factor mRNA by RNA-binding protein HuR. J Biol Chem. 1998;273(11):6417-6423. doi:10.1074/jbc.273.11.6417 
  15. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/ VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond.). 2005;109(3):227-241.  doi:10.1042/cs20040370 
  16. Houck KA. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem. 1992;267(36):26031-26037.
  17. Gogat K. VEGF and KDR gene expression during human embryonic and fetal eye development. Invest Ophthalmol Vis Sci. 2004;45(1):7-14.  doi:10.1167/iovs.02-1096 
  18. Schligemann RO, Van Hinsberg VW. Role of vascular permeability factor/vascular endothelial growth factor in eye disease. Br J Ophthalmol. 1997;81(6):501-512.  doi:10.1136/bjo.81.6.501 
  19. Miller JW, Adamis AP, Aiello LP. Vascular endothelial growth factor in ocular neovascularisation and proliferative diabeticretinopathy. Diabetes & Metabolism. 1997;13(1):37-50.  doi:10.1002/(sici)1099-0895(199703)13:1<37::aid-dmr174>3.0.co;2-k 
  20. Marneros AG. Vascular endothelial growth factor expression in the retinal pigment epithelium is essentialfor choriocapillaris development and visual function. Am J Pathol. 2005; 67:(5):1451-1459. doi:10.1016/s0002-9440(10)61231-x 
  21. Blaauwgeers HG. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrinerelation. Am J Pathol. 1999;155(2):421-428.  doi:10.1016/s0002-9440(10)65138-3 
  22. Aliello LP. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective β-isoform-selective inhibito. Diabetes. 1997;46(9):1473-1480. doi:10.2337/diabetes.46.9.1473 
  23. Antonetti DA. Vascular endothelial growth factor induced rapid phosphorylation of tight junctions protein occludin and zonula occluden 1. J Biol Chem. 1999;274(33):23463-23467. doi:10.1074/jbc.274.33.23463 
  24. Harhaj NS. VEGF activation of protein kinase C stimulates occluding phosphorylation and contributes to endothelial permeability. Invest Ophthalmol Vis Sci. 2006; 47(11):5106-5115. doi:10.1167/iovs.06-0322 
  25. Nicoletti VG. Diabetic patiens and retinal proliferation: an evaluation of the role of vascular endothelial growth factor (VEGF). Experimental And Clinical Endocrinology & Diabetes. 2003;111(4):209-214.  doi:10.1055/s-2003-40465 
  26. Early Treatment Diabetic Retinopathy Study Research Group. The Early Treatment Diabetic Retinopathy Study; design and baseline patient characteristics. ETDRS report number 7. Ophthalmology. 1991;98:741-756.  doi:10.1016/s0161-6420(13)38009-9 
  27. Hofman P. Endotelial cell hypertrophy induced by vascular endothelial growth factor in the retina: new insights into the pathogenesis of capillary nonperfusion. Arch Ophthalmol. 2001;119(6):861-866.  doi:10.1001/archopht.119.6.861 
  28. Li Y. VEGF-B inhibits apoptosis via VEGFR-1-mediated suppression thе expression of BH3-only protein genes in mice and rats. J Clin Invest. 2008;118:913-923.  doi:10.1172/jci33673 
  29. Wong CG. Inravitreal VEGF and bFGF produced florid retinal neovascularization and hemorhrage in rabbit. Curr Eye Res. 2001;22(2):140-147.  doi:10.1076/ceyr.22.2.140.5528 
  30. Alikacem N. Quantitative MR imaging study of sustained release of VEGF in rabbits. Invest Opthalmol Vis Sci. 2000;41(6):1561-1569.
  31. Senger DR. Purication and NH2-terminal amino acid sequence of guinea pig tumor secreted VPF. Cancer Res. 1990;50(6):1774-1778.
  32. Lu M. VEGF increases retinal vascular ICAM-I expression in vivo. Invest Opthalmol Vis Sci. 1999;40(8):1872-1880.
  33. Miyamoto K. In vivo demonstration of increased leukocyte entrapment in retinal microcirculation of diabetic rats. Invest Ophthalmol Vis Sci. 1998;39(11):2190-2194.
  34. Miyamoto K. Vascular endothelial growth factor (VEGF) - induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). Am J Pathol. 2000;156(5):1733-1739. doi:10.1016/s0002-9440(10)65044-4 
  35. Paques M. Evaluation fluorescein-labeled autologous leucocytes for examination for retinal circulation in humans. Curr Eye Res. 2000;21(1):560-565.  doi:10.1076/0271-3683(200007)2111-zft560 
  36. Kuz'min A, Lipatov D, Chistyakov T i dr. Vascular endothelial growth factor in the fluid of the anterior chamber of the eye in patients with diabetic retinopathy, cataract and neovascular glaucoma. Sakharnyi diabet. 2010;(3):32-36. (In Russ.)
  37. Selim KM, Sahan D, Muhittin T. Increased levels of vascular endothelial growth factor in the aqueous humor of patients with diabetic retinopathy. Indian J Ophthalmol. 2010;5(5):375-379.  doi:10.4103/0301-4738.67042 
  38. Funatsu H, Yamashita H, Noma H. Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients. Graefes Arch Clin Exp Ophthalmol. 2005;243(1)3-8.  doi:10.1007/s00417-004-0950-7 
  39. Antonetti DA, Barber AJ, Bronson SK. Perspectives in Diabetes. Diabetes. 2006;55:2401-2411.
  40. Hermann C, Assmus B, Urbich C. Insulin-mediated stimulation of protein kinase Akt: A potent survival signaling cascade for endothelial cells. Arterioscler Thromb Vasc Biol. 2000;20(2):402-409.  doi:10.1161/01.atv.20.2.402 
  41. Mizutani M, Kern TS. Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J Clin Inv. 1996;97(12):2883-2890. doi:10.1172/jci118746 
  42. Durham JT, Herman IM. Microvascular modifications in diabetic retinopathy. Curr Diab Rep. 2011;11(4):253-264.  doi:10.1007/s11892-011-0204-0 
  43. Stem MS, Gardner TW. Neurodegeneration in the pathogenesis of diabetic retinopathy: molecular mechanisms and therapeutic implications. Curr Med Chem. 2013;20(26):3241-3250. doi:10.2174/09298673113209990027 
  44. Chaturvedi NN, Sjoelie AK, Porta M. Markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 diabetes. Diabetes Care. 2001;24:284-289.  doi:10.2337/diacare.24.2.284 
  45. Reiter CN, Wu X, Sandirasegarane L. Diabetes Reduces Basal Retinal Insulin Receptor Signaling. Diabetes. 2006;(55):1148-1156. doi:10.2337/diabetes.55.04.06.db05-0744
  46. Hammes HP, Lin J, Bretzel RG. Upregulation of the Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor System in Experimental Background Diabetic Retinopathy of the Rat. Diabetes. 1998;(47):401-406.  doi:10.2337/diabetes.47.3.401 
  47. Sone H, Kawakami Y, Okuda Y. Ocular vascular endothelial growth factor levels in diabetic rats are elevated before observable retinal proliferative changes. Diabetologia. 1997;40:726-730.  doi:10.1007/s001250050740 
  48. Senger DR. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219(4587):983-985.  doi:10.1126/science.6823562 
  49. Shishkin M. A Differetiated approach to the prescription of angiogenesis inhibitors for diabetic macular edema. Vestnik NMKhTs im. N.I. Pirogova. 2012;7(1):122-127. (In Russ.)
  50. Rusnak S. The Measurement of Intraocular Biomarkers in Various Stages of Proliferative Diabetic Retinopathy Using Multiplex xMAP Technology. J. Ophthalmol. 2015;117:424-783.  doi:10.1155/2015/424783
  51. Li X, Aase K, Li H, von Euler G, Eriksson U. Isoform-specific expression of VEGF-B in normal tissues and tumors. Growth Factors. 2001;19:49-59.  doi:10.3109/08977190109001075 
  52. Li X, Eriksson G, Novel U. VEGF family members: VEGF-B, VEGF-C and VEGF-D. Int J Biochem Cell Biol International. 2001;33:421-426.  doi:10.1016/s1357-2725(01)00027-9 
  53. Li X. VEGF-B: a survival, or an angiogenic factor? Cell Adh Migr. 2009;3(4):322-327.
  54. Li X. Revaluation of the role of VEGF-B suggests a restricted role in the revascularization of the ischemic myocardium. Arterioscler Thromb Vasc Biol. 2008;28:1614-1620. doi:10.1161/atvbaha.107.158725 
  55. Li Y. VEGF-B inhibits apoptosis via VEGFR-1-mediated suppression thеexpression of BH3-only protein genes in mice and rats. J Clin Invest. 2008;118:913-923.  doi:10.1172/jci33673 
  56. Poesen K et al. Novel role for vascular endothelial growth factor (VEGF) receptor-1 and its Ligand VEGF-B in motor neuron degeneration. J Neurosci. 2008;28:10451-10459. doi:10.1523/jneurosci.1092-08.2008 
  57. Reichelt M. Vascular endothelial growth factor-B and retinal vascular development in the mouse. Clin Experiment Ophthalmol. 2003;31:61-65.  doi:10.1046/j.1442-9071.2003.00602.x 
  58. Zhang F, Tang Z, Hou X. VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. Proc Natl Acad Sci USA. 2009;106(15):6152-6157. doi:10.1073/pnas.0813061106 
  59. Cunnick GH, Jiang WG, Douglas-Jones T. Lymphangiogenesis and lymph node metastasis in breast cancer. Mol Cancer. 2008;7:23.  doi:10.1186/1476-4598-7-23 
  60. Lee SK, Cho EY, Kim WW. The prediction of lymph node metastasis in ductal carcinoma in situ with microinvasion by assessing lymphangiogenesis. J Surg Oncol. 2010;102(3):225-229.  doi:10.1002/jso.21607 

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register


We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.